Alumis Inc. (ALMS)

NASDAQ: ALMS · IEX Real-Time Price · USD
-0.01 (-0.08%)
At close: Jul 19, 2024, 4:00 PM
-0.24 (-1.92%)
After-hours: Jul 19, 2024, 4:59 PM EDT
Market Cap 704.62M
Revenue (ttm) n/a
Net Income (ttm) -98.11M
Shares Out 56.37M
EPS (ttm) -1.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,931
Open 12.50
Previous Close 12.51
Day's Range 12.29 - 13.00
52-Week Range 10.45 - 13.53
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 15, 2024

About ALMS

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2024
Employees 109
Stock Exchange NASDAQ
Ticker Symbol ALMS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements


Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

On Friday, Alumis Inc ALMS priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering.

22 days ago - Benzinga

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Shares of biopharmaceutical firm Alumis opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday.

22 days ago - Reuters

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis set the pricing of its U.S. initial public offering at $16 per share, the lower end of its price range, valuing it at around $902 million.

22 days ago - Reuters

Alumis Announces Pricing of Initial Public Offering

Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering

22 days ago - GlobeNewsWire

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.

26 days ago - Reuters

Alumis eyes $300 million in proceeds in IPO

Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint o...

26 days ago - Market Watch

Alumis, a biotech focused on immune-mediated diseases, files for a $100 million IPO

Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 weeks ago - Renaissance Capital

Alumis IPO Registration Document (S-1)

Alumis has filed to go public with an IPO on the NASDAQ.

6 weeks ago - SEC